In light of this evidence, specific trials that consider the use of SGLT2-i in patients with PAD and prospective studies aimed at evaluating the potential protective effect of these drugs against the onset of diabetic foot are necessary. The gene discussed is SLC5A2; the disease is peripheral arterial disease.